News and Trends 14 Dec 2022 Planning application submitted for Europe’s largest life sciences building Canary Wharf Group (CWG) and Kadans Science Partner are submitting a detailed planning application for a commercial health and life sciences building at Canary Wharf, London. The companies said the 23-story 823,000 sq ft tower will be Europe’s largest and most technologically advanced life sciences facility. Energy efficiency is at the forefront of the building’s […] December 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Tachmed aiming to make healthcare more accessible Tachmed is looking to transform access to healthcare through technology. The company’s CEO, Paul Christie, tells us how. What is the driving force behind Tachmed? What motivated you to work towards transforming digital diagnostics technology? It was during my private equity career that the idea of Tachmed was born. I was with a team running […] December 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Blood clotting research holds hope for sepsis Researchers from the University of Birmingham in the U.K., who identified a novel mechanism for platelet activation in pathogenic blood clotting (thrombosis), are now turning their attention to sepsis. Identified by associate professor Julie Rayes and Martina Colicchia from the Birmingham Platelet Group, and described in a recent paper in Blood, this previously unknown axis […] December 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 12 Dec 2022 Artificial intelligence: a new era in rare genetic disease diagnosis Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […] December 12, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 New targeted drug shows benefit against breast cancer in first phase III trial A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […] December 9, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 The Native Antigen Company expands infectious disease portfolio The Native Antigen Company (part of LGC Clinical Diagnostics), today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP). The addition of this latest recombinant protein expands the company’s comprehensive portfolio of antigens and antibodies for infectious diseases and has been designed to support immunoassay and vaccine development. The Native Antigen […] December 9, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, has announced £3.3 million ($4 million) of secured investments. This brings the company’s total funding to date to £7 million ($8.5 million). MicrofluidX’s next generation platform, the Cyto Engine, addresses the need for an affordable, scalable cell culture platform to revolutionize […] December 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, which aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass […] December 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Ibex and Source announce agreement to aid pathologists with diagnostic accuracy An agreement has been announced between Ibex Medical Analytics and Source LDPath, part of Source BioScience. It will expand the deployment of artificial intelligence (AI) to Source’s entire pathology network. Ibex works with AI-powered cancer diagnostics and the expansion builds on its previous work with LDPath. Source, which provides integrated laboratory services and products, acquired […] December 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Owlstone Medical launches Breath Biopsy AOC Atlas built with diverse breath samples Owlstone Medical, a U.K. company working in breath biopsy for applications in early disease detection and precision medicine has announced the launch of the Breath Biopsy AOC Atlas. This is a catalogue of volatile organic compounds (VOCs) found on breath. The Atlas provides insight and scientific context into the molecules, supporting biomarker discovery through incorporation […] December 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 ImaginAb launching clinical trial for renal cancer and malignant melanoma ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which will take place at Hull University Teaching Hospitals NHS Trust in the U.K., will investigate ImaginAb’s investigational CD8 ImmunoPET agent in patients with melanoma or […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email